19 June 2013
Keywords: bbc, documents, regen, zolpidem, study, use, uk
Article | 21 November 2007
Use of UK biotechnology firm ReGen Therapeutics' novel zolpidem formulation as a treatment for the dormancy associated with brain
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
21 November 2007
19 November 2007
© 2013 thepharmaletter.com